{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:09:44Z","timestamp":1793156984257,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007219","name":"Shanghai Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["22ZR1461800"],"award-info":[{"award-number":["22ZR1461800"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Analysis"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jpha.2025.101318","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T19:17:03Z","timestamp":1745263023000},"page":"101318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Unlocking the potential of atractylenolide II: Mitigating non-alcoholic fatty liver disease through farnesoid X receptor-endoplasmic reticulum stress interplay"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7090-262X","authenticated-orcid":false,"given":"Ming","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4664-5977","authenticated-orcid":false,"given":"Zhiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-ru","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpha.2025.101318_bib1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","article-title":"Current status and future trends of the global burden of MASLD","volume":"35","author":"Miao","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.jpha.2025.101318_bib2","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jpha.2025.101318_bib3","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance","volume":"79","author":"Hutchison","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jpha.2025.101318_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41573-021-00320-3","article-title":"Pharmacological targeting of endoplasmic reticulum stress in disease","volume":"21","author":"Marciniak","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jpha.2025.101318_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101169","article-title":"A guide to understanding endoplasmic reticulum stress in metabolic disorders","volume":"47","author":"Lemmer","year":"2021","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.jpha.2025.101318_bib6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/hep.32562","article-title":"Endoplasmic reticulum stress in liver diseases","volume":"77","author":"Ajoolabady","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jpha.2025.101318_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155811","article-title":"Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: Decoding the labyrinth","volume":"154","author":"Dashti","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.jpha.2025.101318_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/bies.202200052","article-title":"Structural basis of the conformational and functional regulation of human SERCA2b, the ubiquitous endoplasmic reticulum calcium pump","volume":"44","author":"Zhang","year":"2022","journal-title":"Bioessays"},{"key":"10.1016\/j.jpha.2025.101318_bib9","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1111\/bph.16160","article-title":"CDN1163, an activator of sarco\/endoplasmic reticulum Ca2+ ATPase, up-regulates mitochondrial functions and protects against lipotoxicity in pancreatic \u03b2-cells","volume":"180","author":"Nguyen","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jpha.2025.101318_bib10","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1074\/jbc.M115.705012","article-title":"Small molecular allosteric activator of the sarco\/endoplasmic reticulum Ca2+-ATPase (SERCA) attenuates diabetes and metabolic disorders","volume":"291","author":"Kang","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jpha.2025.101318_bib11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cbdd.13620","article-title":"SERCA stimulation: A potential approach in therapeutics","volume":"95","author":"Rahate","year":"2020","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.jpha.2025.101318_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100558","article-title":"Pharmacological SERCA activation limits diet-induced steatohepatitis and restores liver metabolic function in mice","volume":"65","author":"Bednarski","year":"2024","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.jpha.2025.101318_bib13","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nature09968","article-title":"Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity","volume":"473","author":"Fu","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jpha.2025.101318_bib14","doi-asserted-by":"crossref","first-page":"19320","DOI":"10.1073\/pnas.1012044107","article-title":"Sarco(endo)plasmic reticulum Ca2+-ATPase 2b is a major regulator of endoplasmic reticulum stress and glucose homeostasis in obesity","volume":"107","author":"Park","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jpha.2025.101318_bib15","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.2337\/db16-0084","article-title":"SERCA2 deficiency impairs pancreatic \u03b2-cell function in response to diet-induced obesity","volume":"65","author":"Tong","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.jpha.2025.101318_bib16","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/nm.4429","article-title":"UCP1-independent signaling involving SERCA2b-mediated calcium cycling regulates beige fat thermogenesis and systemic glucose homeostasis","volume":"23","author":"Ikeda","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.jpha.2025.101318_bib17","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jpha.2025.101318_bib18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41575-020-00404-2","article-title":"The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer","volume":"18","author":"Sun","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jpha.2025.101318_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3350\/cmh.2022.0237","article-title":"Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis","volume":"29","author":"Lee","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.jpha.2025.101318_bib20","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.celrep.2018.07.068","article-title":"FXR inhibits endoplasmic reticulum stress-induced NLRP3 inflammasome in hepatocytes and ameliorates liver injury","volume":"24","author":"Han","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.jpha.2025.101318_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109118","article-title":"FXR controls duodenogastric reflux-induced gastric inflammation through negatively regulating ER stress-associated TNXIP\/NLPR3 inflammasome","volume":"27","author":"Yu","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.jpha.2025.101318_bib22","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/bph.14570","article-title":"Betulinic acid alleviates endoplasmic reticulum stress-mediated nonalcoholic fatty liver disease through activation of farnesoid X receptors in mice","volume":"176","author":"Gu","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jpha.2025.101318_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173735","article-title":"Atractylenolides, essential components of Atractylodes-based traditional herbal medicines: Antioxidant, anti-inflammatory and anticancer properties","volume":"891","author":"Bailly","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jpha.2025.101318_bib24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s12272-021-01342-6","article-title":"Atractylenolides (I, II, and III): A review of their pharmacology and pharmacokinetics","volume":"44","author":"Deng","year":"2021","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.jpha.2025.101318_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cmet.2022.11.012","article-title":"Discovery of a potent allosteric activator of DGKQ that ameliorates obesity-induced insulin resistance via the Sn-1,2-DAG-PKC\u03b5 signaling axis","volume":"35","author":"Zheng","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.jpha.2025.101318_bib26","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1111\/bph.15193","article-title":"The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research","volume":"177","author":"du Sert","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jpha.2025.101318_bib27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0021-9258(18)64849-5","article-title":"A simple method for the isolation and purification of total lipides from animal tissues","volume":"226","author":"Folch","year":"1957","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jpha.2025.101318_bib28","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jpha.2025.101318_bib29","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.cmet.2008.04.011","article-title":"Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice","volume":"7","author":"Oyadomari","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.jpha.2025.101318_bib30","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/med.21991","article-title":"FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid","volume":"44","author":"Wang","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.jpha.2025.101318_bib31","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/s41401-021-00849-4","article-title":"FXR: Structures, biology, and drug development for NASH and fibrosis diseases","volume":"43","author":"Tian","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jpha.2025.101318_bib32","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-018-1685-2","article-title":"Matrine attenuates endoplasmic reticulum stress and mitochondrion dysfunction in nonalcoholic fatty liver disease by regulating SERCA pathway","volume":"16","author":"Gao","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jpha.2025.101318_bib33","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: An adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.jpha.2025.101318_bib34","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1124\/jpet.112.196519","article-title":"Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-\/-) mice","volume":"343","author":"Hambruch","year":"2012","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.jpha.2025.101318_bib35","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jhep.2022.03.017","article-title":"Endoplasmic reticulum-mitochondria miscommunication is an early and causal trigger of hepatic insulin resistance and steatosis","volume":"77","author":"Beaulant","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jpha.2025.101318_bib36","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.molmet.2016.12.001","article-title":"JNK at the crossroad of obesity, insulin resistance, and cell stress response","volume":"6","author":"Solinas","year":"2016","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.jpha.2025.101318_bib37","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1126\/science.aav3722","article-title":"Targeting a ceramide double bond improves insulin resistance and hepatic steatosis","volume":"365","author":"Chaurasia","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jpha.2025.101318_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/science.adi3332","article-title":"Hepatic glycogenesis antagonizes lipogenesis by blocking S1P via UDPG","volume":"383","author":"Chen","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.jpha.2025.101318_bib39","doi-asserted-by":"crossref","first-page":"10455","DOI":"10.1074\/jbc.M117.786525","article-title":"Lack of liver glycogen causes hepatic insulin resistance and steatosis in mice","volume":"292","author":"Irimia","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jpha.2025.101318_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-2128-6","article-title":"eIF2\u03b1-CHOP-BCl-2\/JNK and IRE1\u03b1-XBP1\/JNK signaling promote apoptosis and inflammation and support the proliferation of Newcastle disease virus","volume":"10","author":"Li","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jpha.2025.101318_bib41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41575-022-00717-4","article-title":"NAFLD, MAFLD and obesity: Brothers in arms?","volume":"20","author":"Machado","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jpha.2025.101318_bib42","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/jm401873d","article-title":"Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors","volume":"57","author":"D'Amore","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpha.2025.101318_bib43","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1124\/mol.110.064501","article-title":"Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist","volume":"78","author":"Rizzo","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jpha.2025.101318_bib44","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1053\/j.gastro.2014.08.042","article-title":"The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice","volume":"147","author":"Lieu","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpha.2025.101318_bib45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/med.21921","article-title":"ER stress and inflammation crosstalk in obesity","volume":"43","author":"Ajoolabady","year":"2023","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.jpha.2025.101318_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111422","article-title":"Hepatic ER stress suppresses adipose browning through ATF4-CIRP-ANGPTL3 cascade","volume":"40","author":"Lv","year":"2022","journal-title":"Cell Rep."}],"container-title":["Journal of Pharmaceutical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095177925001352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095177925001352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:16:27Z","timestamp":1777623387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095177925001352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2095177925001352"],"URL":"https:\/\/doi.org\/10.1016\/j.jpha.2025.101318","relation":{},"ISSN":["2095-1779"],"issn-type":[{"value":"2095-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unlocking the potential of atractylenolide II: Mitigating non-alcoholic fatty liver disease through farnesoid X receptor-endoplasmic reticulum stress interplay","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpha.2025.101318","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Xi\u2019an Jiaotong University.","name":"copyright","label":"Copyright"}],"article-number":"101318"}}